the Clinical Outcome of Empagliflozin in Pediatric Heart Failure Patients

the Clinical Outcome of Empagliflozin in Pediatric Heart Failure Patients

the study to investigate the efficacy of empagiflozin in pediatric heart failure

Inclusion Criteria:

• • Pediatrics (aged 1months-18 years)

  • Confirmed HF diagnosis:

HF will be defined by reduced ventricular systolic function (left ventricular ejection fraction by echocardiography) or impaired ventricular filling (pulmonary capillary wedge pressure > 18 mmHg measured directly and/or the ratio of early diastolic mitral inflow velocity(E) to early diastolic mitral annular velocity (e')( E/e'>14 by echocardiography) with clinical features of congestion and/or low cardiac output.

• Class III or IV of ROSS classification or BNP level more than 300 pg/mL

Exclusion Criteria:

• • Pediatric with chronic kidney failure

  • Avoid initiating empagliflozin in patients with concurrent urinary tract infection (UTI).

  • patients with eGFR <60 mL/minute/1.73 m2 will be excluded.

  • Patients with contraindication to empagliflozin usage which include

    • eGFR <30 mL/minute/1.73 m2
    • Hypersensitivity (eg, angioedema) to empagliflozin